This document discusses long-term management of patients with repaired tetralogy of Fallot (rTOF). It notes that while surgical repair dramatically improves life expectancy, rTOF patients remain anatomically, physiologically, and electrophysiologically abnormal. Long-term follow up is needed as annual mortality risk increases over time. Key issues include progressive pulmonary regurgitation, right ventricular dysfunction, interactions between the right and left ventricles, arrhythmias and risk of sudden cardiac death, need for pulmonary valve replacement in some patients, and potential neurodevelopmental outcomes. Imaging modalities like echocardiography and cardiac MRI are important for assessment over time.
Admixture lesions in congenital cyanotic heart diseaseRamachandra Barik
Admixture lesions in congenital cyanotic heart disease
Jaganmohan A Tharakan
Department of Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, India
Admixture lesions in congenital cyanotic heart diseaseRamachandra Barik
Admixture lesions in congenital cyanotic heart disease
Jaganmohan A Tharakan
Department of Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, India
A lecture highlighting the role of Echocardiography as a major hemodynamic monitoring tool in the Intensive Care settings and the assessment of loading conditions.
Pulmonary atresia with intact interventricular septum management Ramachandra Barik
The goals of early palliation of pulmonary atresia with intact ventricular septum (PA-IVS) include the relief of cyanosis and ductal dependence by providing a reliable source of pulmonary blood flow, and the relief of right ventricular outflow tract (RVOT) obstruction to encourage forward flow and growth of right-sided
Idiopathic VT refers to VT occurring in structurally normal hearts in the absence of myocardial scarring. Classification of monomorphic idiopathic VT includes outflow tract VT, fascicular VT, papillary muscle VT,annular VT, and miscellaneous (VT from the body of the RV and crux of
the heart). It is commonly seen in young patients and usually has a benign course. The 12-lead lectrocardiogram is critical in distinguishing the specific form and locations of idiopathic VT. Treatment options include medical therapy specific to the underlying mechanism of VT or catheter
ablation.
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
DISSERTATION on NEW DRUG DISCOVERY AND DEVELOPMENT STAGES OF DRUG DISCOVERYNEHA GUPTA
The process of drug discovery and development is a complex and multi-step endeavor aimed at bringing new pharmaceutical drugs to market. It begins with identifying and validating a biological target, such as a protein, gene, or RNA, that is associated with a disease. This step involves understanding the target's role in the disease and confirming that modulating it can have therapeutic effects. The next stage, hit identification, employs high-throughput screening (HTS) and other methods to find compounds that interact with the target. Computational techniques may also be used to identify potential hits from large compound libraries.
Following hit identification, the hits are optimized to improve their efficacy, selectivity, and pharmacokinetic properties, resulting in lead compounds. These leads undergo further refinement to enhance their potency, reduce toxicity, and improve drug-like characteristics, creating drug candidates suitable for preclinical testing. In the preclinical development phase, drug candidates are tested in vitro (in cell cultures) and in vivo (in animal models) to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics. Toxicology studies are conducted to assess potential risks.
Before clinical trials can begin, an Investigational New Drug (IND) application must be submitted to regulatory authorities. This application includes data from preclinical studies and plans for clinical trials. Clinical development involves human trials in three phases: Phase I tests the drug's safety and dosage in a small group of healthy volunteers, Phase II assesses the drug's efficacy and side effects in a larger group of patients with the target disease, and Phase III confirms the drug's efficacy and monitors adverse reactions in a large population, often compared to existing treatments.
After successful clinical trials, a New Drug Application (NDA) is submitted to regulatory authorities for approval, including all data from preclinical and clinical studies, as well as proposed labeling and manufacturing information. Regulatory authorities then review the NDA to ensure the drug is safe, effective, and of high quality, potentially requiring additional studies. Finally, after a drug is approved and marketed, it undergoes post-marketing surveillance, which includes continuous monitoring for long-term safety and effectiveness, pharmacovigilance, and reporting of any adverse effects.
Antimicrobial stewardship to prevent antimicrobial resistanceGovindRankawat1
India is among the nations with the highest burden of bacterial infections.
India is one of the largest consumers of antibiotics worldwide.
India carries one of the largest burdens of drug‑resistant pathogens worldwide.
Highest burden of multidrug‑resistant tuberculosis,
Alarmingly high resistance among Gram‑negative and Gram‑positive bacteria even to newer antimicrobials such as carbapenems.
NDM‑1 ( New Delhi Metallo Beta lactamase 1, an enzyme which inactivates majority of Beta lactam antibiotics including carbapenems) was reported in 2008
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
4. Introduction
Sx repair: Imp landmark: 1954 Lillhei n team
Complete repair: Dramatically alters life
expectancy; not curative: Anatomically,
physiologically, electro-physiologically abnormal
Long term survival: Not equal to general population:
Annual mortality risk increases by 0.1%per decade
rTOF: Disease needing follow up
4
8. PR
Key hemodynamically significant lesion: Progressive RV
dilatation+ Ventricular dysfunction
Increases with time—> RV volume overload (exacerbated by
distal PA stenosis)
Indications/ methods/ optimal timing of PV replacement:
Debatable
8
9. Determinants of PR
Regurgitant orifice area
RV compliance
Diastolic pressure difference b/w MPA+ RV
Capacitance of PAs
Duration of diastole
9
10. Determinants of PR
cont…
Torricelli principal:
PR Volume= ROA X C X DT X (P2-P1)
ROA: Regurgitation orifice area
C: Constant (empiric number)
DT: Diastolic time
P2-P1: Mean diastolic pressure
difference b/w MPA and RV
10
11. PR pathophysiology
PR depends on:
Diastolic PA/RV gradient: Very little
PV orifice size
PA diastolic pressure depends on vessel recoil after
systole and transmitted pressure from LA
RV diastolic pressure depends on RV compliance
11
13. RV post TOF repair
Pathophysiology of RV remodelling in response to altered hemodynamic
conditions after rTOF: Similar to response of LV to ch. volume overload
Differences with regard to:
Chamber geometry
Myofiber artitecture
Chamber contraction pattern
Coronary artery anatomy and flow dynamics
Disposition of conduction system
Dependency on LV size and function
Although RV function impacts LV function: Reverse much more
pronounced with 63%of RV pressure rise accounted for by LV contraction
13
14. RV post TOF repair
cont…
Relief of RVOT obstruction involves:
Incision of infundibular free wall
Resection of obstructive muscle bundles
Disruption of PV with partial/complete excision
Placement of an outflow patch , often
extending to the plane of PV into MPA
Conduit: RV to PA
VSD patch closure (can impair TV function)
14
16. Insights from CMR
Similar to LV function in severe chronic AR—> Once
compensatory mechanisms of RV fails, Mass: volume ratio
decreases, ES volume increases, EF decreases
Kurotobi et al: Demonstrated association b/w increase in RV
wall stress (afterload), decreased RV EF and symptoms in
rTOF
16
17. rTOF: Factors
affecting RV mechanics
Size of outflow patch
RV fibrosis
Impaired RV diastolic function
LV dysfunction
Prolonged conduction time
Dyssynchrony of RV contraction
Older age of repair
17
19. RV-LV interaction after
TOF repair
RV+ LV functions in series: Similar net outputs in absence of
shunts
Bernheim: 1910
Bernheim effect: Alterations in size+ functions of LV—>
Adversely impact geometry+ function of RV eg: Sev MR—>
Displaces IVS into RV—> Elevates JVP
Reverse Bernheim effect: Alterations in size+ functions of
RV leads to LV dysfunction
19
20. RV-LV interaction after
TOF repair cont…
Superficial spiralling layer of RV myofibers—> Continuous with
superficial layer of LV; Deep layer continuous through IVS
V-V interactions: Ventricles share myofibers, septum, coronary
blood flow, pericardial space
RV volume load—> Septum shifts towards left—> Leftward
shift of LV pressure- volume loop—> Reduced LV volumes
Progressive RV dysfunction—> LV function deteriorates
Ventricular dyssynchrony (Both intra+ inter ventricular):
Contributes to adverse RV-LV interactions
20
21. Physiological factors
linking 2 ventricles…
Blood moved through lungs by RV—> LV preload+ CO
PS+ PR: Threatens LV preload+ CO
Change in shape/ size of RV—> LV also alters
Trans septal pressure gradient: Determines position of
ventricular septum at ED
21
22. Pre op factors affecting
LV function in rTOF
Abnormal CA anatomy
Prolonged periods of deep cyanosis
LV volume overload: Palliative shunts
LVEF on CMR late after TOF repair influenced by:
RVEF
Duration of palliation pre repair
AR
22
23. rTOF: How to follow
up?
History:
Effort intolerance, palpitation, neuro
developmental+ psychiatric evaluation
Examination:
Growth+ development, BP, JVP (Commonly raised-
Restrictive physiology, Prominent V waves if TR)
Cardiomegaly, RV outflow pulsations
Aortic enlargement
23
24. ECG
Rhythm: Sinus/ CHB/ A flutter/ PCVs VT
Axis: RBBB/ QRS duration/ QRS fragmentation
Rt axis: Common, lt axis due to inlet VSD or post op
bifascicular block
24
25. CXR
Heart size
Infundibular enlargement, RVOT aneurysm
RA enlargement in severe TR
Ascending aortic enlargement
Lung vascularity: Differential vascularity from PA
stenosis, collaterals
25
26. ECHO assessment of
rTOF
Residua/ Sequelae/ complications
Residual VSD/ RVOTO
PA stenosis
PR
TR
RV/ LV function
Ascending aorta
Collaterals
26
27. Doppler study
Non invasive hemodynamic information: Useful for
decision making
Assessment of PR severity
Diastolic flow reversal—> Severe PR, esp if in BPAs
PHT (<100msec)+ Jet annulus ratio (>1/3): Best
correlates with CMR severity
27
28. 3D ECHO
Better assessment of PV morphology
Better characterisation of pulmonary flow
Underestimates RV volumes and EF
Low spacial+ temporal resolution
28
29. CMR
Gold standard
Timing a major challenge in India: Availability and
cost
PR fraction
PR volume
RVEDV, RVESV
RV/LV Ratio
RVEF
29
30. Late issues
Interventions: PA stenting, PV replacement,
Pacemaker implantation
Endocarditis
Contraception/ Pregnancy after rTOF
Neurodevelopmental outcomes
30
31. Indications of PVR in patients with
rTOF/ similar physiology with
moderate- severe PR (RF≥25%)
31
40. Arrhythmias after
rTOF
Bradyarrhythmias:
1% CHB after TOF repair—> May recover
Delayed recovery may predict late CHB+SCD
SV arrhythmias:
30% in late f/up
A fib, A flu, focal or re entrant recurrent
tachycardia—> All occur+ cause morbidity—>
CHF/ stroke/ VT/ reoperation/ mortality
40
41. Electromechanical
interactions
Arrhythmias+ SCD: MCC of death post rTOF
Risk factors for SCD (1-5%):
Older age at sx repair
Moderate- severe PR
Sy+ Di dysfunction
Prolonged QRS interval (>180 msec)
CHB beyond 3rd POD
Repair via atriotomy
Male sex
Advanced NYHA class
41
42. Electromechanical
interactions cont…
All pathophysiological mechanisms for arrhythmias present
Electrical instability:
Anatomical modifications following sx
Mechanical events like ventricular dilatation+ stretching
Abnormal fibrous tissues at different sites in RV/LV
Fibrofatty substitution around sx scar- Anatomical substrate
for re-entrant tachycardia
42
43. Contraception/
pregnancy after rTOF
Early education to teenage girls
Recurrence risk/ males too
Mostly can choose from full range on contraception
Cautions with combined hormonal preparations in those with
significant vent dysfunction/ atrial arrhythmias- associated risks
of TE risks of oestrogen
Pregnancy generally well tolerated
Risks of pregnancy depends on severity of residual lesions, deg
of vent dysfunction, likelihood of developing arrhythmia
43
44. IE
Rare after rTOF; but frequency increases after PV
replacement
Patients educated/ oral hygiene
Prophylaxis for those with conduits+ prosthetic
valves
44
45. Aortic root post TOF
repair
Fetus with TOF: Normal aortic root diameter at
diagnosis—> Serial measurement—> Accelerated
growth (esp with severe RVOTO)
At birth: Absolute diameter of aorta increased
Increased volume load on developing aorta
?Histologic/ elastic abnormalities
45
46. Aortic root dilatation
Can cause aortic insufficiency in adults: AV
replacement needed
Extremely rare: Aortic dissection
Studies revealed regression of aortic sinus years
after rTOF
47. Neurodevelopmental
outcomes
Long term f/up: Some impairment in cognitive+
motor development
All pts of rTOF: Appropriate developmental
behavioural surveillance+ screening
47
48. 22q11.2 micro deletion
in TOF
Common association (8-15%)
May be diagnosed for 1st time in adulthood
Dyslexia, behavioural abnormalities+ psychiatric
disorders: Common
Genetic diagnosis allows early recognition+
treatment of non cardiac problem
AD: 50% risk to offspring
48
49. So summing up with take home
message:
Current results of TOF repair
Child with TOF expected corrective surgery by 6 months: >96%
survival to hospital discharge
During childhood: 5% reoperation; 6% catheter interventions
PV replacement needed for 0.8%/year—>TOF-PA or TOF-APV
more likely
For a 30 yrs old rTOF: Annual risk of death 0.5%( Normal risk
0.15% males; 0.06% females)—> Risk increases by 0.1%/ decade
Increasing adverse outcomes with age: Related to
pathophysiology of rTOF
49